- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02927392
Brown Adipose Tissue Activity in Pre- and Postmenopausal Women
The Impact of Estrogen Status on the Biological Function of Brown Adipose Tissue in Women Measured Using Quantitative PET/CT
Study Overview
Detailed Description
Participants will be asked to perform studies to measure resting metabolic rate and activity of brown adipose tissue or brown fat. Brown fat is different from regular "white fat" in that it produces heat and burns calories. The investigators will measure how active brown fat is at normal room temperature and after participants have been exposed to cold.
The study will last 5-6 hours. It will consist of measurements made in warm temperatures and then after a period of cold exposure. For the cold exposure part of the study, participants will be asked to wear a cooling suit for 3 hrs. Skin temperature is normally about 90º Fahrenheit. The cooling suit will adjust the water temperature until your skin temperature is about 82º Fahrenheit. The suit will cover the entire body except for the face, hands, and feet. Participants may feel cold while wearing the suit and you may shiver some, but based on past studies, any shivering should be minor.
Before and after the cooling suit is turned on, body scans will be performed using a procedure called positron emission tomography (PET). These scans do not use radiation. Before the PET scans, the investigators will infuse radioactive tracer into an arm. These tracers have a low dose of radiation and will show us where the brown fat is and how active it is. One PET scan will be performed at room temperature, and the second scan will be performed after the cooling suit has been worn for 3 hours. Two additional scans using computed tomography (CT) will be performed at end of the study. CT scans are like an x-ray, and use radiation. The radiation dose in the CT scan is much higher than the tracers. When the CT scans are combined with the PET scans, we can separate brown fat from white fat.
15 pre-menopausal women will be asked to volunteer for a follow up study. For 5 months, pre-menopausal women in this study will receive monthly injections that contain a study drug (leuprolide) that reduces estrogen to postmenopausal levels. This drug is approved by the FDA to reduce estrogen for the treatment of uterine fibroids and endometriosis, but is not approved for use in healthy women. In this study, the drug is being used to decrease hormones to determine if this reduces brown fat activity. 6 months after the first injection, these women will be asked to repeat the PET/CT studies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Edward Melanson, PHD
- Phone Number: 303-724-0935
- Email: ed.melanson@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Premenopausal volunteers will be healthy, eumenorrheic women, aged 18-45 yrs. Eumenorrheic status will be verified by regular menses (no missed cycles in previous year; cycle length 25-35 d).
- Postmenopausal volunteers will be healthy women who have no menses for at least 12 months
Exclusion Criteria:
- Body mass index (BMI) > 35 kg/m2
Additional exclusion criteria for premenopausal women
- Hormonal contraceptive use (past 6 mo.)
- Pregnant, lactating or intention to become pregnant during the period of study
Additional exclusion criteria for postmenopausal women
- History or current use of hormonal replacement therapy (HRT)
- Women who have undergone surgical menopause.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pre-menopausal women
To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
|
A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
Other Names:
|
No Intervention: Post-menopausal women
To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brown Adipose Tissue Volume
Time Frame: 5-6 hrs
|
Brown adipose tissue volume will be measured using the radioactive tracer 18Fluro-deoxyglucose.
|
5-6 hrs
|
Brown Adipose Tissue Activity -Warm Exposure
Time Frame: 5-6 hrs
|
Brown adipose tissue activity in warm temperatures will be measured using the radioactive tracer 11C-acetate
|
5-6 hrs
|
Brown Adipose Tissue Activity - ColdExposure
Time Frame: 5-6 hrs
|
Brown adipose tissue activity after cold exposure will be measured using the radioactive tracer 11C-acetate
|
5-6 hrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resting energy expenditure - before cold exposure
Time Frame: 5-6 hrs.
|
Resting energy expenditure is the calories burned when a person is at rest.
|
5-6 hrs.
|
Resting energy expenditure - after cold exposure
Time Frame: 5-6 hrs
|
Resting energy expenditure is the calories burned when a person is at rest.
|
5-6 hrs
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward Melanson, Ph.D., University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-1479
- 1R01DK112260-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Leuprolide acetate
-
AbbottCompletedPuberty, PrecociousUnited States, Puerto Rico
-
Camurus ABCompletedPhase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate CancerProstate CancerFinland, Hungary
-
University of UtahUniversity of Chicago; University of MichiganCompletedPrecocious Puberty | Delayed PubertyUnited States
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
Urology of VirginiaFerring PharmaceuticalsCompletedProstate CancerUnited States
-
M.D. Anderson Cancer CenterTAP Pharmaceutical Products Inc.CompletedAmenorrhea | Premature Ovarian Failure | Ovarian Function InsufficiencyUnited States
-
University Magna GraeciaUnknown
-
SOTIO a.s.CompletedProstate CancerCzechia
-
AbbVie (prior sponsor, Abbott)CompletedCentral Precocious Puberty (CPP) | Precocious | Leuprolide Acetate | Luteinizing Hormone (LH) | Gonadotrophin-releasing Hormone Agonist (GnRHa) | Tanner Staging | Depot Formulation | Suppression of LH | Gonadotrophin-releasing Hormone (GnRH) | Lupron | GnRH Analog | Pediatrics Central Precocious PubertyUnited States, Puerto Rico
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); University of Ottawa; Queen's...CompletedCancer | Fertility PreservationCanada